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SUMMARY
Crohn’s disease (CD) is characterised by a transmural
inﬂammatory process, which can affect any part of the
digestive tract; however, CD with oesophageal
presentation is rare. We report a case of a previously
healthy young woman with symptoms of dysphagia,
odynophagia, chest pain and weight loss, who presented
oesophageal ulcers at upper endoscopy and whose
histology revealed granulomatous oesophagitis. After
complementary study, a mild ileocaecal involvement of
CD was demonstrated. The patient became
asymptomatic with proton pump inhibitor and a course
of prednisolone. Mucosal healing was obtained after
maintenance therapy with azathioprine. In the absence
of extraoesophageal symptoms, oesophageal CD may be
overlooked. CD must always be considered as differential
diagnosis in the presence of oesophageal ulcers.
BACKGROUND
Crohn’s disease (CD) is a chronic granulomatous
inﬂammatory disease that may involve any area of
gastrointestinal tract; however, oesophagus involve-
ment is uncommon, with a prevalence of ∼1.8% in
adults.1 Most of diagnosis of oesophageal involve-
ment is made in patients with known CD having
symptoms referred to the oesophagus.2 Rarely is it
the presenting feature of the CD.
CASE PRESENTATION
A 23-year-old white woman was referred to our
outpatient unit after 12 consecutive days of odyno-
phagia, dysphagia and chest pain. The patient
weighed 60 kg and she had already lost 5 kg since
her symptoms began.
She denied other gastrointestinal symptoms.
There was no history of oral ulcers or fever.
Her medical history and family history were not
contributing and she denied taking any medication.
Physical examination was unremarkable.
INVESTIGATIONS
Laboratory test results were signiﬁcant only for
mild C reactive protein of 13.1 mg/L (normal
value: <3.0 mg/L).
Upper endoscopy revealed multiple ulcers with
punched out appearance in the medium and lower
oesophagus with normal surrounding mucosa, as
seen in ﬁgure 1. The gastro-oesophageal junction,
stomach and duodenum were normal.
Histological examination demonstrated oesopha-
geal mucosa with areas of erosion and presence of
epithelioid granuloma without central necrosis in
lamina propria, as seen in ﬁgure 2.
Ziehl-Neelsen stain, immunohistochemical stain-
ing for cytomegalovirus (CMV), herpes simplex
virus (HSV) and PCR for Mycobacterium tubercu-
losis DNA were negative in biopsy specimens. HIV
serology also came up negative.
Chest X-ray was normal and Mantoux test was
negative.
DIFFERENTIAL DIAGNOSIS
The differential diagnoses that should be consid-
ered include gastro-oesophageal reﬂux disease,
oesophageal carcinoma, viral infections (HSV or
CMV), CD, sarcoidosis, tuberculosis, disseminated
fungal disease, Behcet’s syndrome and chronic
granulomatous disease.2–4
OUTCOME AND FOLLOW-UP
She was followed up under close observation as
outpatient and started pantoprazole 40 mg once
daily with improvement of symptoms after 15 days
of treatment.
Figure 1 Oesophageal ulcers.
Figure 2 Microscopic examination of oesophageal
mucosal specimens, arrows: granuloma.
Monteiro S, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2016-217960 1
Reminder of important clinical lesson
Following treatment, repeat upper endoscopy demonstrated
the continuing presence of ulcers in the lower and middle
oesophagus.
An ileocolonoscopy was performed which revealed superﬁcial
ulcers in the ascending colon, caecum and superﬁcial erosions in
terminal ileum, as seen in ﬁgure 3. Histological examination of
terminal ileum biopsies revealed erosion, mild architectural dis-
tortion, mild decreased mucin secretory activity and marked
expansion of the lamina propria by lymphocytic inﬂammatory
inﬁltrate. The colon biopsies revealed mild decreased mucin
secretory activity, focal Paneth cell metaplasia and intense
lymphocytic inﬂammatory inﬁltrate. No granulomas were
identiﬁed.
The patient underwent a complete investigation of the small
bowel by MR enterography that revealed parietal thickening of
the terminal ileum, with early hyperenhancement by the con-
trast product to an extent of ∼10 cm. No complicated disease
such as stenosis, ﬁstula or intra-abdominal collections was
observed.
In this context, the diagnosis of CD was considered and the
patient was started on prednisolone 40 mg once daily tapering
for 4 weeks and azathioprine 150 mg once daily with a full reso-
lution of symptoms after a 1 week of treatment.
After 12 weeks of treatment, a repeated upper endoscopy
revealed healing of the oesophageal mucosa, as seen in ﬁgure 4.
At present, she is asymptomatic, and under azathioprine
150 mg once daily.
DISCUSSION
The involvement of the oesophagus by CD is rare2 and is even
rarer to present as an initial manifestation of the disease,3 5
because in the majority of cases the small bowel or colon
involvement precedes oesophageal disease.2 Few cases have been
reported of isolated oesophageal CD;2 6–9 however, there has
been an increased number of reported cases since the wide-
spread use of upper endoscopy.
Patients with oesophageal CD have symptoms related to their
oesophageal involvement.10 Dysphagia and odynophagia are the
most common symptoms.2 6 Other symptoms include heartburn
and chest pain.2 Up to 30% of patients have oral aphthous
ulcerations2 10 at the time of oesophageal CD symptom onset.
Weight loss associated with these symptoms can be found.3 6 11
Extra intestinal manifestations of CD are often present, includ-
ing arthritis, uveitis, and erythema nodosum.12
Endoscopic ﬁndings of CD oesophageal involvement include
ulcers or erosions surrounded by normal-appearing mucosa, and
cobblestoning of mucosa.13 The most common sites of involve-
ment are the middle or distal oesophagus.2 10
A small percentage of patients may complicate with ﬁstulas to
the stomach,14 respiratory tract,15–22 or have stricture
formation.6 9 23
There are no pathognomonic histological features of oesopha-
geal CD. The most common histological ﬁnding is a lympho-
cytic inﬁltrate in the lamina propria, though this is not speciﬁc.2
Non-caseating granulomas are seldom detected,1 possibly
owing to the patchy nature of disease or the superﬁcial nature
of biopsies. Thus their presence is not strictly necessary for the
diagnosis.
The management of oesophageal CD is not established owing
to a limited number of heterogeneous cases and lack of clinical
trials reported in the literature.
Proton pump inhibitor therapy has been shown to relieve
symptoms,2 24 similar to this case. However, in this case there
was no improvement in the endoscopic ﬁndings. Proton pump
inhibitors efﬁcacy in mucosal healing has not been proven,25
and there is no recommendation for proton pump inhibitor
monotherapy.1 12 26
Similarly, there is no recommendation for topical treatment of
oesophageal CD involvement. However, Rholl et al14 reported
a case of oesophagogastric ﬁstula successfully treated with a
liquid form of mesalamine suspension dose of 4 g daily, prednis-
olone (30 mg prednisone daily), and ranitidine suspension.
Zezos et al11 also reported a case of mucosal healing of
oesophagus treated with swallowed aerosolised budesonide.
Oral systemic steroids are frequently used for oesophageal
CD with most patients improving rapidly,2 27 as has occurred in
this case.
There are also reported cases of efﬁcacy of thiopurines on
patients with oesophageal CD.2
Antitumour necrosis factor therapy has been shown to be
effective in severe16 17 28–30 and refractory30 oesophageal CD.
As oesophageal CD portends a poor prognosis, the threshold
for initiating anti-tumour necrosis factor therapy should be
low.26
Endoscopic dilation may be indicated in cases of symptomatic
oesophageal strictures.2 Surgical resection may be needed in ﬁs-
tulas, refractory strictures, and disease refractory to medical
treatment.2
Temporary enteral nutrition through percutaneous gastros-
tomy proved to be useful to complement medical therapy in
two cases of oesophageal CD.31
In our case, prednisolone induction and azathioprine main-
tenance enabled a clinical and endoscopic remission.
D’Haens et al reviewed clinical and endoscopic follow-up of
14 patients with CD of the oesophagus. According to these
authors, there are three patterns of evolution of CD of the
Figure 4 Oesophagus appearance at 12 weeks after treatment.
Figure 3 Erosions in caecum (left) and in the terminal ileum (right) at
ileocolonoscopy.
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oesophagus: resolution of symptoms and lesions with no relapse
during follow-up in 57.1% of cases (complete healing), persist-
ent lesions despite treatment in 21.4% (persistent lesions),
reappearance of symptoms and oesophageal lesions after initial
resolution in 21.4% of cases (relapse).27
In conclusion, CD should be considered in the differential
diagnosis of oesophageal ulcers, even in the absence of known
CD.
Upper endoscopy should be performed in all patients with
CD with oesophageal symptoms. On the other hand, routine
upper endoscopy can also be useful in diagnostic work-up of all
patients with CD in order to evaluate the extent of disease.
After a conﬁrmed diagnosis of CD based on clinical, endo-
scopic, imaging, and histological ﬁndings, treatment should be
personalised, taking into account the patient’s symptoms,
disease activity, course of disease, phenotype and complications.
Learning points
▸ Oesophagitis as an initial manifestation of Crohn’s disease is
rare.
▸ Crohn’s disease should be considered as differential
diagnosis in presence of oesophageal ulcers, even in
absence of known disease.
▸ Treatment of oesophageal Crohn’s disease should be tailored
to each patient, such as co-medication with proton pump
inhibitors and immunomodulators as optional therapy in an
appropriate clinical setting.
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